Probiotics May Improve Heart Disease Markers, But Evidence Remains Weak

A new systematic review and meta-analysis has examined whether probiotic or synbiotic supplementation can influence glycolipid metabolism in patients with coronary heart disease. The study, conducted by researchers at Hunan University of Chinese Medicine and The First Hospital of Hunan University of Chinese Medicine, analyzed data from six randomized controlled trials involving a total of 296 participants. The primary objective was to evaluate the impact of these microbial supplements on key metabolic indicators, specifically fasting blood glucose and various lipid profiles, which are critical factors in the management of cardiovascular health.

By pooling data from trials published up to May 1, 2026, the authors aimed to provide a comprehensive overview of the current evidence base regarding the potential metabolic benefits of gut microbiota modulation in this specific patient population. The analysis revealed that probiotic or synbiotic supplementation was associated with a statistically significant reduction in fasting blood glucose levels. Based on four studies involving 192 participants, the pooled mean difference was -19.25 mg/dL, with a 95% confidence interval ranging from -32.28 to -6.22 mg/dL and a p-value of 0.004.

This suggests that the supplementation may help lower blood sugar levels in patients with coronary heart disease. Additionally, the same subset of studies indicated a significant increase in high-density lipoprotein cholesterol, often referred to as good cholesterol. The mean difference for HDL-C was 3.70 mg/dL, with a 95% confidence interval from 1.65 to 5.74 mg/dL and a p-value of 0.0004.

These findings point to potential improvements in two specific aspects of glycolipid metabolism, although the clinical significance of these changes requires further context. However, the study did not find significant effects on several other important cardiovascular and metabolic markers. There were no statistically significant differences observed in low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, total cholesterol, or triglycerides levels.

Furthermore, the supplementation did not significantly impact insulin levels, the homeostasis model assessment of insulin resistance, or the quantitative insulin sensitivity check index. Blood pressure measurements, including both systolic and diastolic values, also showed no significant changes. The absence of effects on these broader markers suggests that the metabolic benefits of probiotic or synbiotic supplementation may be limited to specific glucose and HDL-C pathways, rather than providing a comprehensive improvement in overall cardiovascular risk factors.

Regarding safety, the analysis indicated that adverse event rates did not differ significantly between the intervention and control groups. However, the authors noted that the safety evidence was limited by the low number of reported events and wide confidence intervals. This limitation means that while no major safety concerns were identified in this pooled analysis, the data is insufficient to definitively rule out rare or subtle adverse effects.

The trial sequential analysis, a method used to assess the conclusiveness of evidence, showed that the cumulative evidence for both HDL-C and fasting blood glucose did not cross the prespecified monitoring boundaries or reach the required information sizes. This indicates that the current body of evidence is not yet robust enough to draw definitive conclusions about the efficacy of these supplements. The certainty of evidence for all outcomes in this meta-analysis was rated as low or very low.

This rating reflects several methodological limitations, including the small number of included trials and the relatively small sample size of 296 participants. The heterogeneity among the studies was also substantial, with variations in probiotic strains, formulations, doses, and treatment durations. This diversity makes it difficult to generalize the findings to probiotics or synbiotics as a whole category.

Instead, the results are specific to the particular combinations and dosages used in the included trials, which limits the applicability of the findings to broader clinical practice. Geographic limitations further constrain the generalizability of the study's conclusions. Five of the six included trials were conducted in Iran, while only one was conducted in China.

This geographic concentration may limit the applicability of the findings to populations with different dietary patterns, microbiome profiles, ethnic backgrounds, or healthcare systems. Despite the observed associations with improved fasting blood glucose and HDL-C levels, the authors caution that these changes cannot be regarded as direct evidence of cardiovascular benefit. The study did not measure hard cardiovascular outcomes, such as heart attacks, strokes, or mortality.

Therefore, it is unclear whether the metabolic improvements translate into meaningful reductions in cardiovascular events. The lack of hard outcomes is a significant limitation, as it prevents a direct link between the supplementation and improved patient prognosis. In conclusion, while probiotic or synbiotic supplementation may be associated with increased HDL-C and reduced fasting blood glucose levels in patients with coronary heart disease, the evidence remains weak and inconclusive.

The negative trial sequential analysis findings, low certainty of evidence, and lack of hard cardiovascular outcomes highlight the need for further research. The substantial heterogeneity in study designs and the limited geographic diversity of the included trials further limit the generalizability of the findings.

Subject of Research: Systematic review of probiotic effects on glycolipid metabolism in coronary heart disease

Article Title: Effects of probiotic or synbiotic supplementation on glycolipid metabolism in patients with coronary heart disease: a systematic review and meta-analysis

Article References: Bai, Y., Yu, Y., Huang, X., Yang, X., Yu, R., & Xiang, Q. (2026). Effects of probiotic or synbiotic supplementation on glycolipid metabolism in patients with coronary heart disease: a systematic review and meta-analysis. Frontiers in Microbiology, 17, Article 1877366. https://doi.org/10.3389/fmicb.2026.1877366

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1877366

Keywords: coronary heart disease, probiotics, synbiotics, glycolipid metabolism, meta-analysis, cardiovascular health, fasting blood glucose, HDL cholesterol, clinical trials, Effects, probiotic, synbiotic